Research ExplorerPublicationsTwo cycles of doxorubicin, bleomycin, vinblastine, and dacar...

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

Standard

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. / Engert, Andreas; Franklin, Jeremy; Eich, Hans Theodor; Brillant, Corinne; Sehlen, Susanne; Cartoni, Claudio; Herrmann, Richard; Pfreundschuh, Michael; Sieber, Markus; Tesch, Hans; Franke, Astrid; Koch, Peter; De Wit, Maike; Paulus, Ursula; Hasenclever, Dirk; Loeffler, Markus; Müller, Rolf-Peter; Müller-Hermelink, Hans Konrad; Dühmke, Eckhart; Diehl, Volker.

In: J CLIN ONCOL, Vol. 25, No. 23, 23, 2007, p. 3495-3502.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Engert, A, Franklin, J, Eich, HT, Brillant, C, Sehlen, S, Cartoni, C, Herrmann, R, Pfreundschuh, M, Sieber, M, Tesch, H, Franke, A, Koch, P, De Wit, M, Paulus, U, Hasenclever, D, Loeffler, M, Müller, R-P, Müller-Hermelink, HK, Dühmke, E & Diehl, V 2007, 'Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.', J CLIN ONCOL, vol. 25, no. 23, 23, pp. 3495-3502. <http://www.ncbi.nlm.nih.gov/pubmed/17606976?dopt=Citation>

APA

Engert, A., Franklin, J., Eich, H. T., Brillant, C., Sehlen, S., Cartoni, C., Herrmann, R., Pfreundschuh, M., Sieber, M., Tesch, H., Franke, A., Koch, P., De Wit, M., Paulus, U., Hasenclever, D., Loeffler, M., Müller, R-P., Müller-Hermelink, H. K., Dühmke, E., & Diehl, V. (2007). Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J CLIN ONCOL, 25(23), 3495-3502. [23]. http://www.ncbi.nlm.nih.gov/pubmed/17606976?dopt=Citation

Vancouver

Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J CLIN ONCOL. 2007;25(23):3495-3502. 23.

Bibtex

@article{69566e8c139c4898821b0f88ccb49d47,
title = "Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.",
abstract = "PURPOSE: To investigate whether combined-modality treatment (CMT) with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by extended-field radiotherapy (EF-RT) is superior to EF-RT alone in patients with early favorable Hodgkin's lymphoma (HL). PATIENTS AND METHODS: Between 1993 and 1998, 650 patients with newly diagnosed, histology-proven HL in clinical stages IA to IIB without risk factors were enrolled onto this multicenter study and randomly assigned to receive 30 Gy EF-RT plus 10 Gy to the involved field (arm A) or two cycles of ABVD followed by the same radiotherapy (arm B). Results At a median observation time of 87 months, there was no difference between treatment arms in terms of complete response rate (arm A, 95%; arm B, 94%) and overall survival (at 7 years: arm A, 92%; arm B, 94%; P = .43). However, freedom from treatment failure was significantly different, with 7-year rates of 67% in arm A (95% CI, 61% to 73%) and 88% in arm B (95% CI, 84% to 92%; P",
author = "Andreas Engert and Jeremy Franklin and Eich, {Hans Theodor} and Corinne Brillant and Susanne Sehlen and Claudio Cartoni and Richard Herrmann and Michael Pfreundschuh and Markus Sieber and Hans Tesch and Astrid Franke and Peter Koch and {De Wit}, Maike and Ursula Paulus and Dirk Hasenclever and Markus Loeffler and Rolf-Peter M{\"u}ller and M{\"u}ller-Hermelink, {Hans Konrad} and Eckhart D{\"u}hmke and Volker Diehl",
year = "2007",
language = "Deutsch",
volume = "25",
pages = "3495--3502",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "23",

}

RIS

TY - JOUR

T1 - Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

AU - Engert, Andreas

AU - Franklin, Jeremy

AU - Eich, Hans Theodor

AU - Brillant, Corinne

AU - Sehlen, Susanne

AU - Cartoni, Claudio

AU - Herrmann, Richard

AU - Pfreundschuh, Michael

AU - Sieber, Markus

AU - Tesch, Hans

AU - Franke, Astrid

AU - Koch, Peter

AU - De Wit, Maike

AU - Paulus, Ursula

AU - Hasenclever, Dirk

AU - Loeffler, Markus

AU - Müller, Rolf-Peter

AU - Müller-Hermelink, Hans Konrad

AU - Dühmke, Eckhart

AU - Diehl, Volker

PY - 2007

Y1 - 2007

N2 - PURPOSE: To investigate whether combined-modality treatment (CMT) with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by extended-field radiotherapy (EF-RT) is superior to EF-RT alone in patients with early favorable Hodgkin's lymphoma (HL). PATIENTS AND METHODS: Between 1993 and 1998, 650 patients with newly diagnosed, histology-proven HL in clinical stages IA to IIB without risk factors were enrolled onto this multicenter study and randomly assigned to receive 30 Gy EF-RT plus 10 Gy to the involved field (arm A) or two cycles of ABVD followed by the same radiotherapy (arm B). Results At a median observation time of 87 months, there was no difference between treatment arms in terms of complete response rate (arm A, 95%; arm B, 94%) and overall survival (at 7 years: arm A, 92%; arm B, 94%; P = .43). However, freedom from treatment failure was significantly different, with 7-year rates of 67% in arm A (95% CI, 61% to 73%) and 88% in arm B (95% CI, 84% to 92%; P

AB - PURPOSE: To investigate whether combined-modality treatment (CMT) with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by extended-field radiotherapy (EF-RT) is superior to EF-RT alone in patients with early favorable Hodgkin's lymphoma (HL). PATIENTS AND METHODS: Between 1993 and 1998, 650 patients with newly diagnosed, histology-proven HL in clinical stages IA to IIB without risk factors were enrolled onto this multicenter study and randomly assigned to receive 30 Gy EF-RT plus 10 Gy to the involved field (arm A) or two cycles of ABVD followed by the same radiotherapy (arm B). Results At a median observation time of 87 months, there was no difference between treatment arms in terms of complete response rate (arm A, 95%; arm B, 94%) and overall survival (at 7 years: arm A, 92%; arm B, 94%; P = .43). However, freedom from treatment failure was significantly different, with 7-year rates of 67% in arm A (95% CI, 61% to 73%) and 88% in arm B (95% CI, 84% to 92%; P

M3 - SCORING: Zeitschriftenaufsatz

VL - 25

SP - 3495

EP - 3502

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 23

M1 - 23

ER -